In this video, Laleh Melstrom, MD, MS, discusses results from phase 2 ALPACA study presented at ASCO Gastrointestinal Cancers Symposium. The study evaluated a dose ...

CHICAGO, June 2, 2007 -- GEMZAR® (gemcitabine HCl for injection), approved in combination with paclitaxel (Taxol®) in the first-line, post-surgical treatment of metastatic breast cancer, was the ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Paris, France, Monday 31 October 2005 - Attempts to improve the chemotherapeutic efficacy and radiotherapy-sensitivity of the anticancer agent, gemcitabine, using gene therapy have yielded interesting ...

June 10, 2004 (New Orleans) — Results of a phase III trial of front-line therapy with gemcitabine plus paclitaxel compared with paclitaxel alone for the treatment of women with metastatic breast ...

Liposomal gemcitabine in combination with pembrolizumab shows promise in the treatment of advanced solid tumors, according to a study presented at the recent American Society of Clinical Oncology ...

Gemcitabine chemotherapy is used to treat advanced cancers of the breast, ovaries, pancreas, and lungs. It works by disrupting DNA replication, which inhibits a cell’s ability to divide and multiply.

Replacing gemcitabine (Gemzar) with pegylated liposomal doxorubicin in a standard platinum-based regimen improved survival in recurrent ovarian cancer, a phase III trial has shown. In a cohort of ...

Various platinum-based doublets constitute the standard treatments for non-small-cell lung cancer (NSCLC) in patients with good performance status. These regimens have very similar activity, so choice ...